Receptor status of tumor as prognostic factor in patients with bilateral breast cancer

Aim: To determine the receptor status of tumors as prognostic factor in development of bilateral breast cancer (BBC) and factor of prognosis of disease. Patients and Methods: 272 cases of BBC during the period from 1995 to 2011 in different oncological institutions of Ukraine have been analyzed. Res...

Повний опис

Збережено в:
Бібліографічні деталі
Дата:2013
Автори: Tsyhyka, D.Y., Hotko, Y.S., Devinyak, O.T.
Формат: Стаття
Мова:English
Опубліковано: Інститут експериментальної патології, онкології і радіобіології ім. Р.Є. Кавецького НАН України 2013
Назва видання:Experimental Oncology
Теми:
Онлайн доступ:http://dspace.nbuv.gov.ua/handle/123456789/145263
Теги: Додати тег
Немає тегів, Будьте першим, хто поставить тег для цього запису!
Назва журналу:Digital Library of Periodicals of National Academy of Sciences of Ukraine
Цитувати:Receptor status of tumor as prognostic factor in patients with bilateral breast cancer / D.Y. Tsyhyka, Y.S. Hotko, O.T. Devinyak // Experimental Oncology. — 2013. — Т. 35, № 4. — С. 291-294. — Бібліогр.: 11 назв. — англ.

Репозитарії

Digital Library of Periodicals of National Academy of Sciences of Ukraine
Опис
Резюме:Aim: To determine the receptor status of tumors as prognostic factor in development of bilateral breast cancer (BBC) and factor of prognosis of disease. Patients and Methods: 272 cases of BBC during the period from 1995 to 2011 in different oncological institutions of Ukraine have been analyzed. Results: Patients with metachronous BBC with positive status of hormone receptors (HR) of tumors have significantly better indices of overall and progression-free survival (three-years — 95%, five-years — 72%), than patients with HR-negative status (among them nobody has survived over 5 years). In patients with synchronous BBC, the receptor status of tumors has similar influence on the prognosis of survival. Nevertheless, indices of overall survival (65%) and progression-free survival (66%) in HR-positive patients were lower than that at metachronous BBC (overall survival and progression-free survival — 72%). Conclusions: Synchronous breast cancer has more aggressive clinical course than metachronous one. It was determined significant influence of receptor status of tumors on the overall survival and progression-free survival in patients with BBC.